Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1602 Dose-Finding Study in Acute Migraine
NCT01613248Phase 2Completed
- Sponsor
- Allergan
- Start
- Jul 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ubrogepant in migraine (6 arms), sponsored by Allergan. Primary endpoints: Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose, Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose and 3 more. Started Jul 2012; status: completed.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT01613248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01613248.